Millions of women experiencing symptoms of polycystic ovary syndrome (PCOS), now being renamed polyendocrine metabolic ovarian syndrome (PMOS), are increasingly turning to off-label use of GLP-1 drugs such as Ozempic, Mounjaro, and Zepbound. The condition, affecting an estimated 1 in 10 women of reproductive age, is characterized by irregular periods, rapid weight gain, cystic acne, excess hair growth, fatigue, and mental health challenges. Historically, many women with PMOS have faced dismissal from healthcare providers, with advice often limited to weight loss or hormonal birth control, leaving them feeling unheard and searching for more effective solutions.
While PMOS has been commonly reduced to a fertility or weight issue, specialists increasingly recognize it as a complex metabolic disorder. This understanding has contributed to the recent name change and a growing dissatisfaction with existing treatment options, which often only address individual symptoms. As GLP-1 drugs have gained popularity for diabetes and weight loss, women with PMOS are hoping these medications offer a more comprehensive approach.
The shift in treatment seeking is evident in prescription data. According to Truveta, the percentage of women with PMOS prescribed semaglutide or tirzepatide jumped from 2.4% in 2021 to 17.6% by 2025. Dr. Zaher Merhi, a reproductive endocrinologist, noted that approximately 30% of his PMOS patients have already tried GLP-1s before discussing clinical options. Online interest has also surged, with searches for terms like "Ozempic fertility" and "Ozempic babies" showing significant increases over the past year.
Many patients report that the impetus to try GLP-1s often comes from their own research or observing peers, rather than from their doctors. Stories abound of women who have struggled for years to get a diagnosis or effective treatment. For Megan Rappa, who was diagnosed as a teen, her primary care physician prescribed metformin when she mentioned GLP-1s, an approach that proved ineffective. Hillary Stanfield, diagnosed at 26, recalled being told that weight loss was her primary option, feeling that she was merely managing symptoms rather than addressing the root cause of the disorder.
Addressing the Metabolic Roots of PMOS
Insulin resistance is a central feature of PMOS, where the body's inefficient response to insulin leads to excess androgen production by the ovaries, disrupting ovulation. GLP-1 drugs work by improving the body's insulin control. Early studies and anecdotal evidence suggest that these drugs can lead to improved insulin sensitivity, reduced androgen levels, more regular menstrual cycles, and even a return of ovulation, beyond just weight loss. One trial indicated that combining metformin with liraglutide significantly increased pregnancy rates in obese PMOS patients compared to metformin alone, suggesting a potential direct effect on the ovaries.
For patients like Rappa, the benefits have been substantial. After starting Zepbound, she lost 56 pounds and regained energy, experienced milder symptoms, and saw improvements in her bloodwork and overall quality of life. Stanfield described her GLP-1 medication as a long-term tool for managing her metabolic condition, noting a significant quieting of cravings and "food noise."
Challenges in Access and Coverage
A significant barrier to accessing GLP-1s for PMOS is that no drugs are FDA-approved specifically for the condition, making all prescriptions off-label. This often complicates insurance coverage, as insurers typically base coverage on FDA-approved indications. Without a concurrent diagnosis like diabetes or meeting specific BMI criteria for obesity, women often pay out-of-pocket, with monthly costs sometimes exceeding $1,000. While manufacturer discounts can lower this, it remains a financial hurdle.
Furthermore, the long-term necessity of these drugs is still being evaluated, as benefits like weight loss and improved cycles can reverse upon discontinuation. However, as clinical trials progress and evidence mounts, attitudes within the medical community are shifting. Endocrinologists are increasingly viewing GLP-1s as a promising option for women with PMOS, particularly those with obesity or metabolic complications unresponsive to conventional treatments. If ongoing research confirms current findings, GLP-1s could become a recognized first-line therapy for metabolic PMOS in the future.